Document is current
Any future updates will be listed below
-
Authors
Marin, David
Li, Ye https://orcid.org/0000-0001-7727-0875
Basar, Rafet
Rafei, Hind https://orcid.org/0000-0002-5724-4183
Daher, May https://orcid.org/0000-0002-6026-8397
Dou, Jinzhuang
Mohanty, Vakul https://orcid.org/0000-0002-5536-6750
Dede, Merve https://orcid.org/0000-0002-0868-5863
Nieto, Yago
Uprety, Nadima
Acharya, Sunil
Liu, Enli
Wilson, Jeffrey
Banerjee, Pinaki
Macapinlac, Homer A.
Ganesh, Christina
Thall, Peter F. https://orcid.org/0000-0002-7293-529X
Bassett, Roland https://orcid.org/0000-0002-4534-2042
Ammari, Mariam
Rao, Sheetal
Cao, Kai https://orcid.org/0000-0001-5039-021X
Shanley, Mayra https://orcid.org/0000-0003-3739-0287
Kaplan, Mecit https://orcid.org/0000-0003-0079-8617
Hosing, Chitra
Kebriaei, Partow
Nastoupil, Loretta J. https://orcid.org/0000-0001-6071-8610
Flowers, Christopher R.
Moseley, Sadie Mae
Lin, Paul https://orcid.org/0000-0002-0524-267X
Ang, Sonny
Popat, Uday R.
Qazilbash, Muzaffar H.
Champlin, Richard E.
Chen, Ken https://orcid.org/0000-0003-4013-5279
Shpall, Elizabeth J.
Rezvani, Katayoun https://orcid.org/0000-0002-9599-2246
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01CA148600-03, P50CA100632, CA016672, 1 R01CA211044-01)
- License Information
-
More Information
Article History
Received: 17 July 2023
Accepted: 20 December 2023
First Online: 18 January 2024
Competing interests
: D.M., Y.L., R.B., H.R., M.D., N.U., S. Acharya, E.L., P.B., M.S., P.L., S. Ang, R.E.C., E.J.S., K.R. and The University of Texas MDACC have an institutional financial conflict of interest with Takeda Pharmaceuticals. D.M., R.B., E.L., S. Ang, E.J.S., K.R. and The University of Texas MDACC have an institutional financial conflict of interest with Affimed. K.R. participates on the Scientific Advisory Board for GemoAb, AvengeBio, Virogin Biotech, GSK, Bayer, Navan Technologies, Caribou Biosciences, Bit Bio and Innate Pharma. K.R. is the scientific founder of Syena. E.J.S. has served on the Scientific Advisory Board for Adaptimmune, Axio, Celaid, FibroBiologics, Navan Technologies, New York Blood Center and Novartis. The remaining authors declare no competing interests.
